AU5047800A - Breast, gastric and prostate cancer associated antigens and uses therefor - Google Patents

Breast, gastric and prostate cancer associated antigens and uses therefor

Info

Publication number
AU5047800A
AU5047800A AU50478/00A AU5047800A AU5047800A AU 5047800 A AU5047800 A AU 5047800A AU 50478/00 A AU50478/00 A AU 50478/00A AU 5047800 A AU5047800 A AU 5047800A AU 5047800 A AU5047800 A AU 5047800A
Authority
AU
Australia
Prior art keywords
gastric
breast
prostate cancer
associated antigens
cancer associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50478/00A
Inventor
Yuichi Obata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
Original Assignee
Ludwig Institute for Cancer Research Ltd
Ludwig Institute for Cancer Research New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, Ludwig Institute for Cancer Research New York filed Critical Ludwig Institute for Cancer Research Ltd
Publication of AU5047800A publication Critical patent/AU5047800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
AU50478/00A 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor Abandoned AU5047800A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13652699P 1999-05-28 1999-05-28
US60136526 1999-05-28
US15345499P 1999-09-10 1999-09-10
US60153454 1999-09-10
PCT/US2000/014749 WO2000073801A2 (en) 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor

Publications (1)

Publication Number Publication Date
AU5047800A true AU5047800A (en) 2000-12-18

Family

ID=26834386

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50478/00A Abandoned AU5047800A (en) 1999-05-28 2000-05-26 Breast, gastric and prostate cancer associated antigens and uses therefor

Country Status (4)

Country Link
EP (1) EP1259812A2 (en)
JP (1) JP2003518364A (en)
AU (1) AU5047800A (en)
WO (1) WO2000073801A2 (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943236B2 (en) 1997-02-25 2005-09-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6630305B1 (en) 1999-11-12 2003-10-07 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6730477B1 (en) 1998-08-04 2004-05-04 Diadexus, Inc. Method of diagnosing, monitoring and staging breast cancer
US6737040B1 (en) 1998-08-04 2004-05-18 Diadexus, Inc. Method and antibody for imaging breast cancer
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6844325B2 (en) 1998-12-28 2005-01-18 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6680197B2 (en) 1998-12-28 2004-01-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US6518237B1 (en) 1998-12-28 2003-02-11 Corixa Corporation Compositions for treatment and diagnosis of breast cancer and methods for their use
US6958361B2 (en) 1998-12-28 2005-10-25 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6573368B2 (en) 1998-12-28 2003-06-03 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7598226B2 (en) 1998-12-28 2009-10-06 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6586572B2 (en) 1998-12-28 2003-07-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6528054B1 (en) 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6262247B1 (en) * 1999-08-30 2001-07-17 Incyte Genomics, Inc. Polycyclic aromatic hydrocarbon induced molecules
JP5640237B2 (en) * 1999-11-30 2014-12-17 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ リミテッド Isolated nucleic acid molecule encoding a cancer-associated antigen, the antigen itself and uses thereof
WO2001040269A2 (en) 1999-11-30 2001-06-07 Corixa Corporation Compositions and methods for therapy and diagnosis of breast cancer
EP1669371A3 (en) * 1999-12-01 2006-06-21 Genentech, Inc. Composition and methods for the diagnosis of tumours
JP2001161374A (en) * 1999-12-13 2001-06-19 Akihiro Abe Polynucleotide, polypeptide, medicine for treating cancer, and vaccine
US6818419B2 (en) 2000-01-13 2004-11-16 Tularik Inc. IRAK-4: compositions and methods of use
AU2001236782A1 (en) * 2000-02-08 2001-08-20 Agensys, Inc. 34p3d7: a tissue specific protein highly expressed in prostate cancer
WO2001077168A2 (en) * 2000-04-11 2001-10-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
AU2002227365A1 (en) 2000-12-07 2002-06-18 Chiron Corporation Endogenous retroviruses up-regulated in prostate cancer
AU2002231736A1 (en) 2000-12-22 2002-07-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Use of repulsive guidance molecule (rgm) and its modulators
GB0031430D0 (en) 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
WO2002072610A2 (en) * 2001-03-14 2002-09-19 The Regents Of The University Of California Rbp1l1, a novel retinoblastoma binding protein-related gene encoding an antigenic epitope and methods of using thereof
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
AU2002318112B2 (en) * 2001-04-10 2007-12-06 Agensys, Inc. Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
ATE415418T1 (en) * 2001-04-10 2008-12-15 Agensys Inc NUCLEIC ACID AND CORRESPONDING PROTEIN NAMED 121P2A3 FOR THE TREATMENT AND DETECTION OF CANCER
KR100405919B1 (en) 2001-06-05 2003-11-14 주식회사 이매진 Pharmaceutical composition for immunological enhancement comprising N-terminal peptide of p43 as an effective component
DE60235413D1 (en) * 2001-12-07 2010-04-01 Novartis Vaccines & Diagnostic IN PROSTATE CANCER HIGHLY REGULATED ENDOGENIC RETROVIRUS
US7147855B2 (en) 2001-12-07 2006-12-12 Juan Saus GIPs, a family of polypeptides with transcription factor activity that interact with goodpasture antigen binding protein
WO2003089608A2 (en) 2002-04-18 2003-10-30 The General Hospital Corporation Drg11-responsive (dragon) gene family
JP2004057003A (en) * 2002-06-03 2004-02-26 Norihiro Chano Rb1 gene-induced protein (rb1cc1) and gene
AU2003276679A1 (en) 2002-06-13 2003-12-31 Chiron Corporation Vectors for expression of hml-2 polypeptides
EP1380644A1 (en) * 2002-07-08 2004-01-14 Kylix B.V. The use of specified TCF target genes to identify drugs for the treatment of cancer, in particular colorectal cancer, in which TCF/beta-catenin/WNT signalling plays a central role
FR2849039B1 (en) * 2002-12-24 2010-10-01 Centre Nat Rech Scient NOVEL PROTEIN ASSOCIATED WITH CENTROSOMES AND ITS APPLICATIONS
US20070166711A1 (en) 2003-04-15 2007-07-19 Samuels Mark E Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
US20060141528A1 (en) * 2004-05-21 2006-06-29 Aebersold Rudolf H Compositions and methods for quantification of serum glycoproteins
CA2579558A1 (en) * 2004-09-08 2006-03-16 Ludwig Institute For Cancer Research Cancer-testis antigens
CN101277974A (en) 2005-09-30 2008-10-01 阿伯特有限及两合公司 Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use
WO2008047473A1 (en) 2006-10-17 2008-04-24 Oncotherapy Science, Inc. Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
ES2562832T3 (en) 2009-12-08 2016-03-08 Abbvie Deutschland Gmbh & Co Kg Monoclonal antibodies against the RGM protein for use in the treatment of degeneration of the retinal nerve fiber layer
CA2804424C (en) 2010-07-12 2021-03-30 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
DK2807192T3 (en) 2012-01-27 2018-07-23 Abbvie Deutschland COMPOSITION AND PROCEDURE FOR DIAGNOSTICATION AND TREATMENT OF DISEASES RELATED TO NEURITE DEGENERATION
EP2814514B1 (en) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
EP2854842A4 (en) 2012-05-25 2016-11-02 Agenus Inc Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
CA2883569A1 (en) 2012-08-31 2014-03-06 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
EP2931312A4 (en) * 2012-12-13 2016-10-19 Univ Virginia Patent Found Target peptides for ovarian cancer therapy and diagnostics
AU2014233436B2 (en) 2013-03-15 2019-12-05 Atyr Pharma, Inc. Histidyl-tRNA synthetase-Fc conjugates
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
SG11201802286PA (en) 2015-10-08 2018-04-27 Oncotherapy Science Inc Mphosph1-derived peptide, and vaccine including same
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
EP3827263A1 (en) * 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Cancer vaccines for colorectal cancer
CN109055555B (en) * 2018-08-27 2021-09-21 中山大学 Lung cancer early stage metastasis diagnosis marker and kit and application thereof
CN114606324B (en) * 2022-05-10 2022-08-05 上海晟燃生物科技有限公司 Kit and system for assisting low-dose CT in screening lung cancer

Also Published As

Publication number Publication date
EP1259812A2 (en) 2002-11-27
WO2000073801A2 (en) 2000-12-07
WO2000073801A3 (en) 2002-09-12
JP2003518364A (en) 2003-06-10

Similar Documents

Publication Publication Date Title
AU5047800A (en) Breast, gastric and prostate cancer associated antigens and uses therefor
AU2002212527A1 (en) Thermometry-based breast cancer risk assessment
AU2001229682A1 (en) Small cell lung cancer associated antigens and uses therefor
AU2002362454A1 (en) Regulated breast cancer genes
AU2002311869A1 (en) Breast cancer-associated genes and uses thereof
AUPR395801A0 (en) Antibodies against cancer
AU2001290860A1 (en) Spas-1 cancer antigen
AU2002349543A1 (en) Tumor antigens
AU2003302165A8 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
AU2948199A (en) Breast cancer antigen
MXPA02004942A (en) Use of anti idiotypical antibodies as vaccines against cancer.
AU6278300A (en) Tumor-associated antigen (r11)
AU2001288921A1 (en) Human breast cancer biomarkers
AU3283500A (en) Tumor-associated antigen
AU5632500A (en) Cancer associated antigens and uses therefor
ZA200203166B (en) Treatment of cancer.
HUP0202270A2 (en) Antitumor antibodies, proteins, and uses thereof
AU1392801A (en) Casb7434, an antigen over-expressed in colon cancer
AU2002326318A1 (en) Targeting tumor cell antigens: antibodies useful for the diagnosis, prognosis, and treatment of cancer
AU2194301A (en) Breast pad
AU2002363807A1 (en) Breast cancer associated polypeptide
AU5162400A (en) Cancer associated antigens and uses therefor
AU4553100A (en) Tumour-associated antigen
AU7788600A (en) Colon-tumour-associated antigens
AU4598100A (en) Treating cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase